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| INTRODUCTION
Kisspeptin is a bioactive peptide that was identified in 2001 [1] [2] [3] and that is localized in the hypothalamic arcuate nucleus and the anteroventral periventricular nucleus in the brain. 4, 5 Estrogen receptors are present in kisspeptin neurons and are thought to play a role in mediating the positive and negative feedback of estrogen and in regulating gonadotropin-releasing hormone secretion. 6, 7 In contrast, recently it has been reported that kisspeptin is expressed in granulosa-lutein cells and theca cells in the ovary. [8] [9] [10] There are reports that, if a kisspeptin antagonist is locally administered to the ovary, delayed vaginal opening and a disorder of the estrous cycle occur, 11 and that mice heterozygous for kisspeptin receptors are in the same state as premature ovarian failure. 12 Additionally, it has been reported that an increase in the corpus luteum is observed when kisspeptin is administered to rat ovaries. 13 These results suggest that kisspeptin is involved in follicular development and ovulation, but its mechanism is still unclear.
It is known that kisspeptin in the periphery is localized in the pancreas, small intestine, and placenta, 1 besides the ovary, and research on it as a biomarker of various diseases is proceeding. [14] [15] [16] In the reproductive field, it has been reported that plasma kisspeptin levels are increased in adolescent patients with polycystic ovary syndrome 17 and they rise during the pre-ovulatory phase and the luteal phase across the menstrual cycle. 18, 19 However, there has been no report of the plasma kisspeptin levels during the ovarian stimulation that is associated with in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).
In contrast, follicular fluid contains various hormones and cytokines and the relationships with egg maturity and IVF results have been studied. [20] [21] [22] [23] [24] There are reports that egg maturity correlates significantly with growth hormone, insulin-like growth factor-I, and estradiol (E2) concentrations in the follicular fluid 20 and that E2 and progesterone (P4) concentrations in the follicular fluid are significantly higher when mature eggs are present
21
; the relationship between the E2 concentration in the follicular fluid and egg maturity is well known.
However, there has not been any report on the concentration of kisspeptin in the follicular fluid and it is not known whether kisspeptin is present in the follicular fluid and whether it is related to various clinical events or egg maturity.
The purpose of this study was to measure the kisspeptin concentrations in the follicular fluid for the first time and to examine their relationship with patients' clinical characteristics, such as their age, number of follicles, number of eggs collected, and serum sex hormone levels. As the sex hormone's level in the blood is greatly affected by the number of growing follicles 25, 26 and there is a possibility that the association with the kisspeptin concentration could be masked, the associations between the serum E2 levels and number of growing follicles, E2 and number of retrieved oocytes, and E2 and number of matured eggs and the follicular fluid kisspeptin levels also were investigated.
The correlation with the E2 concentration in the follicular fluid additionally was examined and the possibility that the concentration of kisspeptin in the follicular fluid might be an indicator of egg maturity was evaluated. Finally, how the plasma kisspeptin levels fluctuate across the ovarian stimulation that is associated with IVF/ICSI was assessed. was scheduled 35 hours after hCG injection.
| MATERIALS AND METHODS

| Patients
Then, 2-6 days after IVF/ICSI, one (n = 19) or two (n = 2) embryos were transferred in each cycle. In the patients with moderate-to-severe 
| Sample collection
In total, 65 samples of follicular fluid were obtained from 30 patients.
During the oocyte retrieval, each follicle was punctured and the follicular fluid was aspirated and collected individually. Only blood-free, clear-yellow follicular fluid aspirates were included in this study.
Follicular fluid from follicles that contained no egg was not included in this study. The samples were centrifuged 200xg and frozen at −80°C.
The patients' venous blood samples also were collected on the day of the OPU to investigate the relationship between the plasma kisspeptin levels and the follicular fluid kisspeptin levels.
In order to investigate the plasma kisspeptin levels across different phases of assisted reproductive technology, venous blood samples were collected from 14 patients (including five patients whose follicular fluid samples were collected for this study) who had been treated with buserelin acetate at the beginning of stimulation (phase I), on the day the schedule for the OPU was decided (2-6 days before OPU) (phase II), and on the days of the OPU (phase III) and ET (phase IV).
In addition, venous blood samples were collected in phase II from all the patients as a routine for hormonal analysis. After collecting the blood, the serum fraction and the plasma fraction were separated rapidly by a centrifuge and frozen at −80°C until assayed. The plasma and follicular fluid samples' characteristics are summarized in Table 1 .
| Hormonal analysis
In all the follicular fluid samples, the E2 levels were measured by chemiluminescence immunoassay. In the blood samples of phase II, the serum E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) also were measured by chemiluminescence and P4 was measured by enzyme immunoassay. The E2 levels on the days prior to the OPU were revised as the rate of the exponential rise of serum E2 to 0.50. 
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The minimal detectable concentration was 0.06 ng/mL. The intraassay variation and interassay variation were <10% and <15%, respectively. The linear range was 0.06-0.9 ng/mL.
The principle of the enzyme immunoassay with this kit is as follows.
The immunoplate is precoated with a secondary antibody and non- 
| Statistical analysis
The normality of all the studied parameters was checked with the chi-square test of goodness-of-fit. Comparisons of the means between each phase were performed with a repeated-measures singlefactor ANOVA. In order to identify which specific means differed, the paired t-test was used. Comparisons between the mean plasma kisspeptin and the follicular fluid kisspeptin concentrations were performed with Welch's t test. Spearman's or Pearson's coefficients were used to assess the correlation of kisspeptin with each parameter. The level of significance was set at P < .05. The software that was used for statistical analysis was Statcel (v.4; OMS Publishing, Inc., Tokorozawa, Japan).
| RESULTS
With 39 patients, there was a total of 476 oocytes, 264 of which were fertilized (55.5%). Nine out of 21 patients who underwent ET were pregnant and the pregnancy rate per ET was 42.9% (Table 1) .
| Follicular fluid kisspeptin levels and plasma kisspeptin levels
In the 65 follicular fluid samples, the kisspeptin concentration averaged 15.090 ± 4.357 pg/mL and ranged from 7.564 to 27.901 All blastocysts were cryopreserved (N) 11 3 8
Blastocysts were not obtained and embryo transfer was impossible (N) 
| Plasma kisspeptin levels during controlled ovarian stimulation in in vitro fertilization/ intracytoplasmic sperm injection
In the 14 of those who were patients being treated with buserelin acetate, the plasma kisspeptin levels were different in the different phases of the IVF/ICSI program. The maximum concentrations of kisspeptin were observed on the day of the OPU (phase III) and on the day of the ET (phase IV). There was a significant increase (P < .05) in the plasma kisspeptin levels from the beginning of stimulation (phase I) to phase III (5.620 ± 2.285 pg/mL to 7.754 ± 2.104 pg/mL) and from phase I to phase IV (5.620 ± 2.285 pg/mL to 7.212 ± 2.831 pg/mL) ( Table 2 ).
| DISCUSSION
For the first time, the kisspeptin concentrations were measured in follicular fluid and it was found that kisspeptin was present in the follicular fluid. The follicular fluid kisspeptin levels were significantly higher than the plasma kisspeptin levels and this is considered to reflect the In addition, there has been a report that the higher that the serum estradiol : oocyte ratio is, the higher the maturity of the egg becomes, This experiment showed that the plasma kisspeptin levels in IVF/ ICSI increased significantly with ovarian stimulation. This is consistent with previous reports that the concentration of kisspeptin is seen to increase during the pre-ovulatory period and the luteal phase during the menstrual cycle. 18, 19 It is known that kisspeptin is expressed in the ovarian granulosa-lutein cells and theca cells of growing follicles [8] [9] [10] and In rat studies, it is known that the expression level of KiSS-1 messenger RNA in the immature ovary is low and it is increased with pregnant-mare serum gonadotropin-hCG stimulation. Values are the mean ± SD of the plasma kisspeptin levels in each phase of ART. Phases III and IV were significantly higher than phase I. Phase I, the beginning of stimulation (after menstruation); Phase II, the day the schedule for the ovum pick-up (OPU) was decided (2-6 days before the OPU); Phase III, the day of the OPU (35 h after the 10 000 IU human chorionic gonadotrophin injection); Phase IV, the day of the embryo transfer (2-6 days after the OPU).
